@article{535cb7aeb1cc4e8fa2d5ff9ef1a60c58,
title = "When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor",
author = "J. Gill and V. Prasad",
note = "Funding Information: VP receives royalties from his book Ending Medical Reversal , his work is funded by Arnold Ventures , he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, and professional societies, is a writer for Medscape and the host of the Plenary Session podcast, which receives crowdfunding support through the Patreon platform. JG declares no competing interests.",
year = "2020",
month = mar,
doi = "10.1016/j.annonc.2019.11.021",
language = "English (US)",
volume = "31",
pages = "328--330",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",
}